

Please add the following new claims:

• - 29. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibiting compound.

B 2

30. The combination of Claim 29 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

3. 31. The combination of Claim 29 wherein the other HIV protease inhibiting compound is Ro 31-8959.

4. 32. The combination of Claim 29 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the other HIV protease inhibiting compound are each formulated as separate compositions.

5. 38. The combination of Claim 32 wherein the formulation of (2S,3S,5S)-5-(N-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at the same time.

34. The combination of Claim 32 wherein the formulation of (2S,3S,5S)-5-(N-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at different times.

7. 35. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and Ro 31-8959.

8. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-

180

hydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibiting compound.

9.

37. The combination of Claim 36 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

10.

38. The combination of Claim 36 wherein the other HIV protease inhibiting compound is Ro 31-8959.

B2

(con't.)

11.

39. The combination of Claim 36 wherein (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the other HIV protease inhibiting compound are each formulated as separate compositions.

12.

40. The combination of Claim 39 wherein the formulation of (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at the same time.

13.

41. The combination of Claim 39 wherein the formulation of (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the other HIV protease inhibiting compound are to be administered at different times.

14.

42. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and Ro 31-8959.

15.

43. (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and another HIV protease inhibitor for concomitant administration for the treatment of an HIV infection.

16.

44. (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-

hydroxyhexane or a pharmaceutically acceptable salt thereof and Ro 31-8959 for concomitant administration for the treatment of an HIV infection.

45. A combination pharmaceutical agent for administration to a human for the treatment of an HIV infection comprising:

- a) a first pharmaceutical composition comprising (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and
- b) a second pharmaceutical composition comprising another HIV protease inhibiting compound.

46. The combination of Claim 45 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

47. The combination of Claim 46 wherein the other HIV protease inhibiting compound is Ro 31-8959.

48. Use of (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for concomitant administration to a human with another HIV protease inhibiting compound for the treatment of an HIV infection.

49. The use of Claim 48 wherein the other HIV protease inhibiting compound is selected from the group consisting of Ro 31-8959, SC-52151, KNI-227 and KNI-272.

50. The use of Claim 48 wherein the other HIV protease inhibiting compound is
Ro 31-8959.

51. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof for use in the treatment of an HIV infection for concomitant administration with another HIV protease inhibiting compound.


52. (2S,3S,5S)-5-(N-(N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof for use in the treatment of an HIV infection for concomitant administration with Ro 31-8959. - -

192

Favorable action on the claims is respectfully requested.

Respectfully submitted,

D. Kempf, et al.



Dr. Steven R. Crowley
Registration No. 31,604
Agent for Applicant

Abbott Laboratories
D-377/AP6D-2
100 Abbott Park Road
Abbott Park, IL. 60064-3500
Telephone: (847) 937-9516 SRC/mac

0382252-03602
264025

